



State-of-the-Art Vaccine Researches

Guest Editors:

Dr. Omar Rossi

GlaxoSmithKline (GSK), Vaccines
Institute for Global Health S.R.L.
(GVGH), Siena, Italy

Dr. Gianmarco Gasperini

GlaxoSmithKline (GSK), Vaccines
Institute for Global Health S.R.L.
(GVGH), Siena, Italy

Dr. Carlos Giannelli

GlaxoSmithKline (GSK), Vaccines
Institute for Global Health S.R.L.
(GVGH), Siena, Italy

Deadline for manuscript
submissions:

closed (1 November 2024)

Message from the Guest Editors

mRNA vaccine took the center of the scene and represented a game changer for the speed of response to pandemic, however several question marks remain in regards to durability of response and breadth of applicability to bacterial targets. In parallel, extensive and fast growing knowledge was established for novel platforms like protein nanoparticles and viral vectors for DNA delivery as well as for more traditional ones like recombinant proteins and glycoconjugates. Finally, innovative adjuvant systems and alternative delivery were largely investigated to improve the magnitude and quality of the immune response induced by vaccination.

This special issue is focused on recent scientific knowledge and current state of the art technologies. Based on your extensive experience, we invite you to contribute with an original research to highlight: novel data obtained with state of the art technologies; comparison of different vaccine platforms in terms of the resulting immunogenicity; innovative combination of vaccine antigens in high-valency formulations, and strategies to maximize immune responses against vaccine targets through alternative delivery and adjuvant systems.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)